Technical analysis of Equillium, Inc. (EQ): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.
Price Performance
| 1 month | -21.06% |
| 3 months | -39.18% |
| Year-to-date | +19.68% |
| 1 year | +21.24% |
| 3 years | +126.22% |
| 5 years | -70.92% |
52-Week Range
| 52-week High | $3.54 |
| 52-week Low | $0.76 |
| Avg Volume (90d) | 725K |
Technical Indicators
| SMA 50 | $2.38 |
| SMA 200 | $2.03 |
| Beta | 1.74 |
| 30-day Volatility (annualised) | 91.7% |
| Price vs SMA 50 | -21.9% |
| Price vs SMA 200 | -8.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.41 | |
| 2025-11 | $0.90 | -36.0% |
| 2025-12 | $1.55 | +71.8% |
| 2026-01 | $1.42 | -8.4% |
| 2026-02 | $1.82 | +28.2% |
| 2026-03 | $2.00 | +9.9% |
| 2026-04 | $2.04 | +2.0% |
| 2026-05 | $2.90 | +42.2% |
| 2026-06 | $3.20 | +10.3% |
| 2026-07 | $2.20 | -31.2% |
| 2026-08 | $2.27 | +3.2% |
| 2026-09 | $1.85 | -18.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $0.03 | $1M |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
Price
| Price | $1.85 |
| Market Cap | $117M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.70 |
| EV / EBITDA | -5.22 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 23.40 |